ArticleNature communications2025
Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A transferrin receptor-targeted liposome for iron metabolism regulation-augmented photodynamic therapy in glioblastoma.Bioactive materials · 2027Article
- Post-translational modification-regulating biomaterials for regeneration.Bioactive materials · 2026Review
- Overcoming hepatic tropism: Precision engineering of lipid nanoparticles for extrahepatic RNA delivery.Materials today. Bio · 2026Review
- Red Blood Cells as Endogenous Biotweezers for Optical Micromanipulation In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.Inflammopharmacology · 2026Review
- Ultrasound-activated dual-targeted liposomes for visualized precise neuromodulation against myocardial ischemia-reperfusion injury.Materials today. Bio · 2026Article
- Aptamer-liposome targeted nanotherapeutics for cancer therapy: Bibliometric analysis, recent developments and future perspectives.Materials today. Bio · 2026Review
- Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Design Strategies and Applications of Engineered Nanoparticles for Traumatic Brain Injury.International journal of nanomedicine · 2026Review
- Deciphering the Impact of Protein Corona on Biological Fate of Nanomedicine-loaded Microneedles.Current drug metabolism · 2026Article
- Inhaled Targeted Nano-Drug Delivery Systems for COPD: Precision Solutions to Clinical Barriers.International journal of nanomedicine · 2026Review
- Local drug delivery systems for the periodontal microenvironment: from barrier penetration to multilevel synergy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Ligand-targeted nanomedicines provide precise delivery, enhance drug accumulation, and reduce side effects, but their clinical translation is hindered by challenges like protein corona formation, which can mask targeting ligands and impair functionality, and complex manufacturing processes. Here we develop galloylated liposomes (GA-lipo) by incorporating gallic acid-modified lipids into lipid bilayers, enabling the stable and controlled adsorption of targeting ligands through non-covalent physical interactions. This approach preserves ligand orientation and functionality, ensuring that binding sites remain exposed even in the presence of a protein corona. As a proof of concept, a weakly basic derivative of DXd (DXdd) is remotely loaded into liposomes, followed by trastuzumab adsorption, achieving 95% encapsulation efficiency for DXdd in 100 nm liposomes (with each trastuzumab molecule delivering approximately 580 DXdd molecules). These trastuzumab-functionalized immunoliposomes exhibit improved tumor inhibition in an SKOV3 tumor model, demonstrating the potential of GA-lipo as a simple and effective approach for constructing targeted nanomedicine delivery systems. This method overcomes key challenges in targeted drug delivery technologies, providing a scalable solution with broad clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.